Evidence map›Paper›PMID 34863149›Full record

ArticleBMC cancer2021

Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.

Chiara Giacomelli, Janine Jung, Astrid Wachter, Susanne Ibing, Rainer Will, Stefan Uhlmann, Heiko Mannsperger, Özgür Sahin, Yosef Yarden, Tim Beißbarth and 3 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. MicroRNAs: A Link between Mammary Gland Development and Breast Cancer.International journal of molecular sciences · 2022
    Review
  7. 5'isomiR-183-5p|+2 elicits tumor suppressor activity in a negative feedback loop with E2F1.Journal of experimental & clinical cancer research : CR · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 4 countries.

Chiara GiacomelliDivision of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany. chiara.giacomelli.1987@gmail.com.ORCID http://orcid.org/0000-0003-1466-1371
Janine Jung *Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Astrid Wachter *Medical Bioinformatics, University Medical Center Göttingen, Göttingen, Germany.
Susanne IbingDivision of Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Rainer WillGenomics and Proteomics Core Facility, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Stefan UhlmannDivision of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heiko MannspergerDivision of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Özgür SahinDivision of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Yosef YardenDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Tim BeißbarthMedical Bioinformatics, University Medical Center Göttingen, Göttingen, Germany.
Ulrike KorfDivision of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Cindy KörnerDivision of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Stefan WiemannDivision of Molecular Genome Analysis, German Cancer Research Center (DKFZ), Heidelberg, Germany. s.wiemann@dkfz-heidelberg.de.
German Cancer Research Center · DEUniversitätsmedizin Göttingen · DEUniversity of South Carolina · USWeizmann Institute of Science · IL

Funding

baden-württemberg stiftung BWST_NCRNA_035bundesministerium für bildung und forschung e:Med FKZ:031A429helmholtz-gemeinschaft German Israeli Helmholtz Research School in Cancer Biology
6 · The paper itself

Abstract

backgroundTriple negative breast cancer (TNBC) is the most aggressive subtype of breast cancer (BC). Treatment options for TNBC patients are limited and further insights into disease aetiology are needed to develop better therapeutic approaches. microRNAs' ability to regulate multiple targets could hold a promising discovery approach to pathways relevant for TNBC aggressiveness. Thus, we address the role of miRNAs in controlling three signalling pathways relevant to the biology of TNBC, and their downstream phenotypes.

methodsTo identify miRNAs regulating WNT/β-catenin, c-Met, and integrin signalling pathways, we performed a high-throughput targeted proteomic approach, investigating the effect of 800 miRNAs on the expression of 62 proteins in the MDA-MB-231 TNBC cell line. We then developed a novel network analysis, Pathway Coregulatory (PC) score, to detect miRNAs regulating these three pathways. Using in vitro assays for cell growth, migration, apoptosis, and stem-cell content, we validated the function of candidate miRNAs. Bioinformatic analyses using BC patients' datasets were employed to assess expression of miRNAs as well as their pathological relevance in TNBC patients.

resultsWe identified six candidate miRNAs coordinately regulating the three signalling pathways. Quantifying cell growth of three TNBC cell lines upon miRNA gain-of-function experiments, we characterised miR-193b as a strong and consistent repressor of proliferation. Importantly, the effects of miR-193b were stronger than chemical inhibition of the individual pathways. We further demonstrated that miR-193b induced apoptosis, repressed migration, and regulated stem-cell markers in MDA-MB-231 cells. Furthermore, miR-193b expression was the lowest in patients classified as TNBC or Basal compared to other subtypes. Gene Set Enrichment Analysis showed that miR-193b expression was significantly associated with reduced activity of WNT/β-catenin and c-Met signalling pathways in TNBC patients.

conclusionsIntegrating miRNA-mediated effects and protein functions on networks, we show that miRNAs predominantly act in a coordinated fashion to activate or repress connected signalling pathways responsible for metastatic traits in TNBC. We further demonstrate that our top candidate, miR-193b, regulates these phenotypes to an extent stronger than individual pathway inhibition, thus emphasizing that its effect on TNBC aggressiveness is mediated by the coordinated repression of these functionally interconnected pathways.

Indexed as

beta CateninCell Line, TumorCell ProliferationHumansMicroRNAsNeoplasm MetastasisProto-Oncogene Proteins c-metTransfectionTriple Negative Breast NeoplasmsWnt Signaling Pathwaybeta CateninMET protein, humanMicroRNAsMIRN193 microRNA, humanProto-Oncogene Proteins c-metc-Met signallingIntegrin signallingmicroRNAsTriple negative breast cancerWNT/β-catenin

Identifiers

PMID34863149
PMCPMC8642942
OpenAlexW4226083547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.